Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer.
Chiappino I, Destefanis P, Addeo A, Galetto A, Cucchiarale G, Munoz F, Zitella A, Ferrando U, Fontana D, Ricardi U, Tizzani A, Bertetto O. Chiappino I, et al. Among authors: fontana d. Am J Clin Oncol. 2007 Jun;30(3):234-8. doi: 10.1097/01.coc.0000256706.16313.49. Am J Clin Oncol. 2007. PMID: 17551298 Clinical Trial.
Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.
Berruti A, Fara E, Tucci M, Tarabuzzi R, Mosca A, Terrone C, Gorzegno G, Fasolis G, Tampellini M, Porpiglia F, De Stefanis M, Fontana D, Bertetto O, Dogliotti L; Gruppo Onco-Urologico Piemontese, Rete Oncologica Piemontese. Berruti A, et al. Among authors: fontana d. Urol Oncol. 2005 Jan-Feb;23(1):1-7. doi: 10.1016/j.urolonc.2004.06.003. Urol Oncol. 2005. PMID: 15885575 Clinical Trial.
Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasia.
Zitella A, Berruti A, Destefanis P, Mengozzi G, Torta M, Ceruti C, Casetta G, Mosca A, Greco A, Rolle L, Aimo G, Aroasio E, Tizzani A, Dogliotti L, Fontana D; Gruppo Oncologico Urologico Piemontese (GOUP). Zitella A, et al. Among authors: fontana d. Clin Chim Acta. 2007 Feb;377(1-2):103-7. doi: 10.1016/j.cca.2006.08.034. Epub 2006 Sep 5. Clin Chim Acta. 2007. PMID: 17034778
Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy.
Sacerdote C, Guarrera S, Ricceri F, Pardini B, Polidoro S, Allione A, Critelli R, Russo A, Andrew AS, Ye Y, Wu X, Kiemeney LA, Bosio A, Casetta G, Cucchiarale G, Destefanis P, Gontero P, Rolle L, Zitella A, Fontana D, Vineis P, Matullo G. Sacerdote C, et al. Among authors: fontana d. Int J Cancer. 2013 Oct 15;133(8):2004-9. doi: 10.1002/ijc.28186. Epub 2013 Apr 25. Int J Cancer. 2013. PMID: 23553206 Free PMC article.
Shorter leukocyte telomere length is independently associated with poor survival in patients with bladder cancer.
Russo A, Modica F, Guarrera S, Fiorito G, Pardini B, Viberti C, Allione A, Critelli R, Bosio A, Casetta G, Cucchiarale G, Destefanis P, Gontero P, Rolle L, Zitella A, Fontana D, Frea B, Vineis P, Sacerdote C, Matullo G. Russo A, et al. Among authors: fontana d. Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2439-46. doi: 10.1158/1055-9965.EPI-14-0228. Epub 2014 Sep 18. Cancer Epidemiol Biomarkers Prev. 2014. PMID: 25234236
Editorial comment.
Fontana D, Destefanis P. Fontana D, et al. Urology. 2009 Dec;74(6):1263; author reply 1263. doi: 10.1016/j.urology.2009.07.1262. Urology. 2009. PMID: 19962523 No abstract available.
362 results